LRRK2 levels in immune cells are increased in Parkinson’s disease

D.A Cook, Emory University
G.T Kannarkat, Emory University
A.F Cintron, Emory University
Laura M. Butkovich, Emory University
Kyle B. Fraser, University of Alabama at Birmingham
J. Chang, Emory University
N. Grigoryan, Emory University
S.A Factor, Emory University
Andrew B. West, University of Alabama at Birmingham
J.M Boss, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: npj Parkinson's Disease
Volume: Volume 3, Number 1
Publisher: Nature Publishing Group | 2017-12
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/s41531-017-0010-8
Permanent URL: https://pid.emory.edu/ark:/25593/s3b70

Final published version: http://dx.doi.org/10.1038/s41531-017-0010-8

Copyright information:

Copyright © The Author(s) 2017

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed January 6, 2024 5:09 PM EST
LRRK2 levels in immune cells are increased in Parkinson’s disease

D. A. Cook¹, G. T. Kannankat¹, A. F. Cintrón¹, Laura M. Butkovich¹, Kyle B. Fraser², J. Chang¹, N. Grigoryan¹, S. A. Factor³, Andrew B. West², J. M. Boss⁴ and M. G. Tansey¹

Mutations associated with leucine-rich repeat kinase 2 are the most common known cause of Parkinson’s disease. The known expression of leucine-rich repeat kinase 2 in immune cells and its negative regulatory function of nuclear factor of activated T cells implicates leucine-rich repeat kinase 2 in the development of the inflammatory environment characteristic of Parkinson’s disease. The aim of this study was to determine the expression pattern of leucine-rich repeat kinase 2 in immune cell subsets and correlate it with the immunophenotype of cells from Parkinson’s disease and healthy subjects. For immunophenotyping, blood cells from 40 Parkinson’s disease patients and 32 age and environment matched-healthy control subjects were analyzed by flow cytometry. Multiplexed immunoassays were used to measure cytokine output of stimulated cells. Leucine-rich repeat kinase 2 expression was increased in B cells (p = 0.0095), T cells (p = 0.029), and CD16¹ monocytes (p = 0.01) of Parkinson’s disease patients compared to healthy controls. Leucine-rich repeat kinase 2 induction was also increased in monocytes and dividing T cells in Parkinson’s disease patients compared to healthy controls. In addition, Parkinson’s disease patient monocytes secreted more inflammatory cytokines compared to healthy control, and cytokine expression positively correlated with leucine-rich repeat kinase 2 expression in T cells from Parkinson’s disease but not healthy controls. Finally, the regulatory surface protein that limits T-cell activation signals, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), was decreased in Parkinson’s disease compared to HC in T cells (p = 0.029). In sum, these findings suggest that leucine-rich repeat kinase 2 has a regulatory role in immune cells and Parkinson’s disease. Functionally, the positive correlations between leucine-rich repeat kinase 2 expression levels in T-cell subsets, cytokine expression and secretion, and T-cell activation states suggest that targeting leucine-rich repeat kinase 2 with therapeutic interventions could have direct effects on immune cell function.

npj Parkinson’s Disease (2017) 3:11; doi:10.1038/s41531-017-0010-8

INTRODUCTION

Parkinson’s disease (PD) is a progressive age-related movement disorder. The histopathological features of PD include degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies (neuronal inclusions of aggregated α-synuclein and other ubiquitinated proteins). Despite decades of extensive study, the etiology of the sporadic form of PD remains unclear. Thus, the development of therapies and therapeutics has been slow-paced. In 2004, multiple labs identified mutations in the leucine-rich repeat kinase 2 (LRRK2) gene as causative for a dominantly inherited form of PD, leading to an exciting new pathway for researchers to pursue.¹, ²

Mutations have also been found in sporadic cases at rates varying from 0.3–4.1% depending on the country of origin and ethnicity of the population studied.³ Due to similarities in the clinical presentation of LRRK2-associated PD and idiopathic PD,³–⁵ the study of LRRK2 function has the potential to offer new insight into the mechanisms underlying sporadic PD etiology.

The LRRK2 gene is large, containing 51 exons that code for a 2527- amino acid protein of large molecular weight (≈286 kDa) with several different functional and protein-interacting domains.⁶–⁷ Enzymatic domains include a ROC (Ras of complex) GTPase domain⁸ and a serine/threonine kinase domain.⁹ There are also multiple protein-interacting domains, including a leucine-rich repeat domain, a C-terminal WD40 repeat domain, and armadillo and ankyrin repeat domains.⁶, ⁷ Given the multiple, highly diverse enzymatic and protein interacting domains, it is likely that LRRK2 may have different binding partners in different cell types. In support of this, LRRK2 has been shown in vitro to influence regulation of autophagy, macroautophagy,¹⁰ ceramide metabolism,¹¹ neurite outgrowth, vesicular trafficking, cytoskeletal components, and cell signaling pathways involving nuclear factor of activated T cells (NFAT), Wnt, and nuclear factor-κB.¹²–¹⁷

Multiple mutations and normal genetic variations in the LRRK2 gene have been associated with disease.¹⁸ The six most common pathogenic mutations in LRRK2 associated with PD¹⁹ reside in the GTPase and kinase domains.¹⁰, ¹¹ The most prevalent mutation is the G2019S mutation in the kinase domain.⁵ Although mutations in LRRK2 only account for 1–2% of all PD cases, they are particularly prevalent in individuals of Ashkenazi Jewish (29.7%) and North African Arab ancestry (41%) (ref. 3). The penetrance of the most common LRRK2 mutation (G2019S) ranges from 28% at 54 years of age to 74% at 79 years of age, suggesting that genetic
and environmental modifiers influence lifetime risk for PD in individuals with these mutations.

Importantly, LRRK2 is not only expressed in neurons but is also expressed in cells of both the innate and adaptive immune system.22, 23 Interestingly, LRRK2 polymorphisms have been associated with Crohn’s disease, an autoimmune inflammatory bowel disease, and leprosy, an infection caused by Mycobacterium leprae, supporting a link to immune function.24, 25 LRRK2 is also a member of the receptor interacting protein kinase family, which are proteins that detect and respond to cellular stress by regulating cell death and activation of the immune system.26, 27 Pro-inflammatory signals, such as interferon-γ (IFN-γ),23, 28 lipopolysaccharide (LPS),22, 30 and interleukin (IL)-1β (ref. 17) have been shown to increase LRRK2 expression. Specifically, in CD14+ macrophages, CD3+ T cells, and CD19+ B cells, increases in LRRK2 following IFN-γ stimulation have been observed.23, 26, 29 Also, IFN-γ stimulation was shown to increase LRRK2 mRNA and protein expression in the non-classical CD14+CD16+ monocyte population.28 Pharmacological inhibition of LRRK2 with multiple inhibitors resulted in decreased CD14, CD16, and major histocompatibility complex (MHC-II) expression, suggesting that LRRK2 may play a significant role in the activation of monocytes via IFN-γ.28 In addition, use of LRRK2 inhibitors results in decreased LRRK2 protein expression after 24 h exposure in peripheral blood mononuclear cells (PBMCs).31 Recently, it was reported that increased expression of LRRK2 in monocytes following IFN-γ stimulation occurs via a mechanism involving extracellular signal-related kinase 5 (ERK5) signaling.29

Despite a growing wealth of evidence that LRRK2 is enriched in both innate and adaptive immune cells,22, 23 to date the majority of studies involving LRRK2 and its associated mutations have mainly been assessed for their effects on neuronal function. Given that increased inflammation in the periphery and the brain has been associated with the pathophysiology of PD,22–24 it is possible that LRRK2 may play a role in this process and serve as a regulator of inflammatory and immune responses that influence age-related degeneration and risk for PD. Based on the current literature, we hypothesized that LRRK2 expression is increased in cells from PD patients, causing a dysregulation of function and activation in cells of both the innate and adaptive immune system. To test this, we investigated the extent to which peripheral immune cell types express LRRK2 and inflammatory cytokines under resting conditions and during immune activation in healthy individuals and in patients with sporadic PD.

RESULTS
Validation of Abcam c41-2 LRRK2 antibody for detection of human LRRK2 by flow cytometry
The c41-2 Abcam LRRK2 (MJFF2) antibody is a rabbit polyclonal antibody used in the studies herein to detect human LRRK2 protein in peripheral immune cell populations. Because the LRRK2 antibody was not conjugated to a fluorophore, a fluorescein isothiocyanate (FITC)-conjugated secondary anti-rabbit IgG antibody was not conjugated to a fluorophore, and the c41-2 LRRK2 antibody in T cells, B cells, and monocytes isolated from human peripheral blood (Supplementary Fig. S1a). Next, naive TH-1 cells were found to express low amounts of LRRK2 protein. Upon treatment with PMA, the cells differentiate into macrophages and following stimulation with IFN-γ, their expression of LRRK2 protein can be shown to increase by western blot (Fig. 1a, b). Importantly, this increase is accompanied by an increase in the LRRK2 signal by flow cytometry (Fig. 1c) using the c41-2 LRRK2 antibody and either of two different secondary antibodies (Alexa-Fluor647 or FITC). In addition, human primary monocytes isolated from peripheral blood were found to express detectable levels of human LRRK2 protein by western blotting with c41-2 (Fig. 1a, b) and by flow cytometry with the same LRRK2 antibody (Fig. 1c). As was seen in the cell lines, the levels of LRRK2 in the primary cells could be increased further by stimulation with IFN-γ as measured by western blot (Fig. 1a, b) and flow cytometry (Fig. 1c).

PD is associated with increased LRRK2 expression in innate and adaptive immune cells
To investigate if LRRK2 levels differ between specific immune cell populations and between healthy individuals and those with PD, immunophenotyping of peripheral blood was performed in cells from PD and age-matched healthy control (HC) subjects. LRRK2 expression has been reported in both monocytes and B cells,22, 23 however, there are conflicting reports as to whether LRRK2 is expressed in T cells.22, 28 To date, the most commonly used approach to ascertain LRRK2 expression levels has been western blotting and quantitative reverse transcriptase-polymerase chain reaction. Differences between antibodies and oligonucleotide primers could account for discrepancies between assays and labs. We found that LRRK2 protein levels, reported as median fluorescence intensity (MFI), were increased in CD16+ monocytes, T cells, and B cells from PD patients compared to HC (Fig. 2a, b). Importantly, the increase in LRRK2 is not a reflection of overall increases in protein content in immune cells in PD subjects vs. HCs as other cell-specific markers such as CD19, CD14, and 4-1BB were not significantly different between HC and PD subjects (Supplementary Fig. S2).

Given the diverse functions associated with T-cell subsets, we determined whether the increased LRRK2 levels in the PD group were altered in all subsets or only specific subsets. The data were stratified by CD8+ effector subsets and CD4+ effector, helper, and regulatory subsets (Supplementary Table 3). We found no significant difference in LRRK2 expression between different T-cell subsets, but its levels are globally increased in all subsets in PD patients compared to HC subjects (Fig. 2c–e). One small exception is the CD4+ Teff subset; when comparing the PD and HC subjects the p-value was 0.051. In our study cohort, patients with PD had increased LRRK2 expression in T cells, B cells and a pro-inflammatory subset of monocytes (CD16+).

In addition to protein expression levels in immune cells, we assessed the frequencies of immune cell populations in our subjects. No significant differences between PD and HC in the
that this decrease is due strictly to the CD4+ subset and not to consistent with what has been previously reported, it appears that there was a positive correlation between the expression level of CD14+ monocytes. Although not reaching significance, there was a trend towards the correlations between LRRK2 expression is induced by inflammatory stimuli in both PD and HC subjects. There are several reports indicating that LRRK2 expression in immune cells increases following inflammatory stimuli such as IFN-γ or microbial components like LPS. We sought to replicate these data in monocytes and explore whether this paradigm held true in T cells. Cells were plated immediately following isolation from peripheral blood. Monocytes were stimulated with IFN-γ for 18 or 72 h. After 18 h of stimulation, LRRK2 levels were not significantly increased (Fig. 4a). However, by 72 h after stimulation, LRRK2 levels in monocytes were significantly increased relative to baseline in both PD and HC populations (Fig. 4a). MHC-II, also known as human leukocyte antigen (HLA), is the antigen-presenting-molecule expressed on cells such as monocytes that activates CD4+ T cells and is upregulated following an inflammatory stimulus. In humans, there are three different isotypes, HLA-DR, -DQ, and -DP, encoded by the MHC-II locus. To determine if there were any alterations in antigen presentation in patients with PD, we assessed expression levels of HLA-DR and -DQ. Both PD and HC groups displayed induction of HLA-DR and -DQ proteins after IFN-γ stimulation with 80–90% of cells being HLA-DR/-DQ double positive (Fig. 4b). Monocytes from both HC subjects and PD patients were upregulated HLA-DR over time (Fig. 4c). Both groups also upregulated HLA-DR over time; however, HC subjects downregulated HLA-DR after 72 h while monocytes from PD patients retained expression (Fig. 4d). Furthermore, after 18 h of stimulation, LRRK2 levels were positively correlated with HLA-DR MFI (Fig. 4e) in monocytes of PD subjects and negatively correlated with HLA-DQ MFI (Fig. 4f) in monocytes from HC patients. In summary, LRRK2 protein expression was induced in monocytes from both groups after stimulation with IFN-γ at both 18 and 72 h post-stimulation. However, LRRK2 expression was positively correlated with MHC-II induction in PD patients and negatively correlated in HC subjects.

LRRK2 induction is slower in T cells compared to monocytes in both PD and HC subjects. To determine the timing of LRRK2 induction following T-cell activation, T cells were stimulated with anti-CD3/CD28-coated beads and IL-2 (a cytokine necessary for T-cell activation and proliferation) for 18 or 72 h. Stimulation for 18 h was not sufficient to induce increases in LRRK2; however, LRRK2 levels after 72 h of stimulation were significantly increased in both CD4+ and CD8+ T cells in PD and HC groups. There were no significant differences between the means of LRRK2 expression in CD4+ T cells in PD and HC after 72 h stimulation (Fig. 5a).
PD is associated with higher LRRK2 induction in proliferating T cells compared to HCs.

To determine if LRRK2 may be involved in regulation of T-cell proliferation, cells were stained with CellTrace Violet, a cell proliferation dye, and analyzed via flow cytometry. Typically, after 72 h of stimulation T cells will have divided between three and four times. To simplify this analysis, each cell division was analyzed individually for LRRK2 expression. We found that LRRK2 induction in proliferating T cells was not significantly different between the two groups, the LRRK2 MFI in CD8+ T cells was higher in PD patients than in HC subjects at every percent of proliferated cells (Supplementary Fig. S4b).

The T-cell activation marker CTLA4 is significantly decreased in T cells of PD patients following stimulation.

In addition to proliferation, we also assessed potential differences in activation markers normally upregulated following stimulation in T cells. If LRRK2 has a role in regulating processes involved in immune cell activation, increased expression levels of LRRK2 should correlate with differential activation of T cells. We looked at two common activation markers: CTLA-4, a negative regulator of activation, and 4-1BB, a receptor that amplifies T-cell activation by inducing secretion of IL-2. CTLA-4 competes with CD28 to bind CD80/86 on antigen-presenting cells; but while CD4+ T cells was not significantly different between the two groups, the LRRK2 MFI in CD8+ T cells was higher in PD patients than in HC subjects at every percent of proliferated cells (Supplementary Fig. S4b).

Fig. 2 LRRK2 expression in T cells, B cells, and a subset of monocytes is increased in PD patients compared to matched HC subjects. LRRK2 median fluorescence intensity (MFI) in monocytes (t(47) = 3.02, p = 0.004, HC n = 21, PD n = 28), and T cells (t(63) = 2.35, p = 0.022, HC n = 29, PD n = 36), a subset of monocytes (t(44) = 2.68, p = 0.01, HC n = 17, PD n = 29) and T-cell subsets (CD4+, (61) = 2.17, p = 0.034, HC n = 29, PD n = 34; CD8+, (65) = 2.39, p = 0.02 HC n = 31, PD n = 36; T helper HC n = 27, PD n = 34: Th1, (t(59) = 2.49, p = 0.016; Th2, (t(59) = 2.41, p = 0.019; Th17, (t(59) = 2.24, p = 0.029; Treg, (t(55) = 2.06, p = 0.044 HC n = 26, PD n = 31; CD4+ effector subsets HC n = 26, PD n = 33: Tcm (t(57) = 2.08, p = 0.043; Naive (t(57) = 2.18, p = 0.033; Tem (t(57) = 2.02, p = 0.049; Teff, (t(57) = 1.99, p = 0.051; CD8+ effector subsets HC n = 22, PD n = 33: Tcm (t(53) = 2.95, p = 0.005; Naive (t(53) = 3.16, p = 0.003; Tem (t(53) = 2.81, p = 0.007; Teff (t(53) = 2.70, p = 0.009) was determined by flow cytometry staining of total peripheral blood mononuclear cells. Means were plotted with standard error of the mean. Two-tailed Student’s t-test between HC and PD was used to test for significance. *p < 0.05, **p < 0.01.
CD28 sends an activating signal when bound, CTLA-4 sends an inhibitory signal when bound. After the 72 h stimulation, both PD and HC T cells upregulated 4-1BB (Supplementary Fig. S2) and in inhibitory manner as compared to HC T cells (HC CD4+ T cells (HC R²(20) = 0.886, p = 0.001, R²(36) = 0.125, p = 0.034); R²(1, 62) = 3.23, p = 0.077), CD16+ monocytes (HC R²(17) = 0.004, p = 0.822, PD R²(29) = 0.006, p = 0.684; F(1,42) = 0.148, p = 0.703), and B cells (HC R²(23) = 0.002, p = 0.860, PD R²(28) = 0.003, p = 0.773; F(1, 45) = 0.092, p = 0.763) and significantly more TNF compared to cells from HC PD patients (Fig. 6d). Interestingly, at 72 h, IL-12p70 was the only cytokine secreted at higher levels in PD T cells compared to HC T cells (Fig. 6d). In summary, several immune cell subsets from PD patients secreted higher cytokines upon stimulation compared to immune cells from HC subjects.

LRRK2 expression is positively correlated with cytokine expression in PD patients

PD patients had higher LRRK2 expression in cells with a higher amount of intracellular cytokine levels (Fig. 7a, b). T cells from PD patients displayed an association between LRRK2 protein levels and cytokine expression (Fig. 7a, b). LRRK2 protein levels positively correlated with IFN-γ, TNF, and IL-2 expression in T cells from PD patients; however, only IFN-γ expression in CD4+ T cells correlated with LRRK2 protein levels in HC subjects (Fig. 7a). In addition, when comparing the two subject groups for interaction, only the correlation between IL-2 expression in CD8+ T cells and LRRK2 MFI displayed significantly different slopes (Fig. 7b). In summary, LRRK2 levels positively correlated with cytokine expression and secretion in PD but not HC subjects.

DISCUSSION

Recent new discoveries in immune cells have suggested a potential link for LRRK2 to the regulation of the immune system and modulation of inflammatory responses. Herein, we demonstrate that LRRK2 is expressed in both innate and adaptive human immune cells and is expressed at higher levels in the immune cells of patients with late-onset PD compared to age-matched HC individuals. In addition, LRRK2 is induced in both human
monocytes and T cells following an inflammatory stimulus; and in PD patients there is a positive correlation between LRRK2 levels, MHC-II induction, cytokine expression and secretion levels, and dampened expression of the T-cell inhibitory factor CTLA-4. Given the established role of LRRK2 as a potential negative regulator of NFAT, the differences we observed between PD patients and HC subjects suggest that LRRK2 may be important in the regulation of both innate and adaptive immune cells within the context of PD. Of note, within our study population and similar to other study populations, the PD group was predominantly male while the HC group was predominantly female as they were generally the spouses and caregivers of the PD patients. To ensure that the differences we observed were not due to this unequal sex distribution, results were stratified by sex but did not affect the differences observed between PD and HC groups.

The increased levels of LRRK2 associated with PD suggest that the protein is contributing to disease pathogenesis. CD14+CD16+ monocytes are considered to represent a non-classical monocyte population that is characteristically more pro-inflammatory and typically display increased cytokine secretion and greater antigen presentation. Therefore, the finding that LRRK2 levels are notably increased in CD16+ monocytes of PD patients compared to classical CD16- monocytes. In addition, it has been shown that circulating monocytes are dysregulated in PD, displaying a hyperactive inflammatory phenotype. The monocyte data taken together with the increased LRRK2 expression in T cells and B cells suggest that following an inflammatory challenge, individuals with PD will mount an exacerbated inflammatory response compared to healthy individuals that could lead to sustained immune activation and acceleration of disease progression.

In support for the role of LRRK2 in immune cell regulation, we found that LRRK2 protein expression increases in human immune cells following inflammatory challenges. Thereafter, LRRK2 levels continue to increase over time in monocytes. Monocytes are antigen-presenting cells that are critical to the activation of the innate and adaptive immune responses. Therefore, the finding that LRRK2 levels are increased in CD14+CD16+ monocytes of PD patients may have functional relevance to disease risk or progression given that it was recently reported that IFN-γ induces more LRRK2 in this subset of monocytes compared to classical CD16- monocytes.
adaptive immune response by upregulating MHC-II (HLA-DR/-DQ) proteins loaded with antigens that activate CD4+ T cells. Although we observed no differences in the overall extent of MHC-II induction between the PD and HC groups, in HC subjects, LRRK2 expression is negatively correlated with HLA-DQ expression whereas in PD patients, LRRK2 expression is positively correlated with HLA-DR expression. These data suggest that LRRK2 could be regulating the antigen presentation function of human monocytes, and that such regulation is altered in PD patients. Studies have shown that inhibition of LRRK2 kinase activity with the LRRK2-IN1 inhibitor decreased expression of CD14, CD16, and MHC-II in monocytes.28 However, due to the reported off-target effects of LRRK2-IN1, specifically ERK5 inhibition,44 it is possible that this decrease cannot be attributed wholly to LRRK2 kinase activity. Alternatively, it is possible that LRRK2 localizes and associates with binding partners involved in regulation of antigen presentation and that LRRK2 kinase activity is not required for such interactions. In addition, recent studies suggest that antigen presentation is altered in a subset of individuals with PD in association with a non-coding SNP (rs 3129882) in the MHC-II locus that synergizes with environmental exposures to increase risk for PD.45 Although the LRRK2 and MHC-II loci are encoded on different chromosomes, perhaps the mechanism of altered antigen presentation increases susceptibility for sporadic PD.

Previous studies have declared LRRK2 absent or undetectable in T-cell populations,28 however, the data presented here definitively demonstrate inducible expression of LRRK2 not just in CD3+ T cells, but also in all functional T-cell subsets. There were no significant differences between baseline levels of LRRK2 in subsets of T cells; however, LRRK2 levels were increased in all of the T cells of PD patients relative to those of HC subjects. Given that LRRK2 has been shown to be a negative regulator of NFAT in HEK293 cells,16 and NFAT is a necessary transcription factor for T-cell activation, we hypothesize that LRRK2 could also serve as a negative regulator of T-cell activation via interaction with NFAT. Induction of LRRK2 was also seen in T cells, but was delayed until 72 h and only seen in dividing T cells. PD patients also had greater upregulation of LRRK2 in these dividing T cells, raising the interesting possibility that LRRK2 is essential for T-cell division or acting in some sort of regulatory capacity during T-cell division.

Fig. 5  The anti-CD3/CD28-stimulated increase in LRRK2 protein in T cells is slower than in monocytes and similar in PD and HC subjects but T-cell proliferation is associated with greater increases in LRRK2 protein and dampened expression of the negative regulator of T-cell activation CTLA4 in PD subjects. LRRK2 median fluorescence intensity (MFI) of a stimulated cells (HC 18 h n = 14, 72 h n = 16, p = 0.019; PD 18 h n = 22, 72 h n = 20, p < 0.0001; HC to PD at 72 h, p = 0.0809), b proliferating cells (CellTrace Violet) (p = 0.0045, HC n = 12, PD n = 11) and c CTLA-4 MFI (HC n = 16, PD n = 20, CD8+ p = 0.0034) were measured using flow cytometry following stimulation of paramagnetically, positively selected T cells with 30 U/mL IL-2 and anti-CD3/CD28 stimulation beads for 72 h. Means were plotted with standard error of the mean. Two-way ANOVA with Sidak’s multiple comparisons post-hoc test was used to test for significance. *p < 0.05, **p < 0.01, ***p < 0.001.
Markers of T-cell activation such as CTLA-4 and 4-1BB are good indicators of proper immune response and regulation. Immune cells upregulate these markers following stimulation to keep the inflammatory response in check. Interestingly, T cells from PD patients have an impaired capacity to upregulate CTLA-4 compared to those from HCs. CTLA-4 transcription is controlled by NFAT1 binding to the proximal promoter and is decreased when NFAT is inhibited. Therefore, our findings suggest that in healthy individuals LRRK2 is a negative regulator of T-cell activation. Specifically, the increase in LRRK2 induced by stimulation acts to limit NFAT-dependent transcription, as evidenced by reductions in expression of CTLA-4. In PD patients, alterations in
LRRK2 levels in PD immune cells
D A Cook et al.

Fig. 7 LRRK2 protein in stimulated CD4+ and CD8+ T cells from PD patients displays significant positive correlations with cytokine-expression. Fold change in percent of cytokine secretion (IFN-γ, TNF, and IL-2) by a CD4+ T cells (IFN-γ: PD R2(20) = 0.339, p = 0.002, HC: R2(13) = 0.307, p = 0.049; F(1, 29) = 0.106, p = 0.747; TNF: PD R2(20) = 0.421, p = 0.002, HC R2(13) = 0.028, p = 0.585; F(1, 29) = 3.63, p = 0.067; IL-2: PD R2(20) = 0.293, p = 0.0014, HC R2(13) = 0.044, p = 0.494; F(1, 29) = 2.19, p = 0.150) and b CD8+ T cells (IFN-γ: PD R2(22) = 0.400, p = 0.002, HC R2(14) = 0.040, p = 0.494; F(1, 32) = 2.04, p = 0.163; TNF: PD R2(22) = 0.398, p = 0.002, HC R2(14) = 0.031, p = 0.549; F(1, 32) = 2.65, p = 0.113; IL-2: PD R2(22) = 0.430, p = 0.001, HC R2(14) = 0.007, p = 0.780; F(1, 32) = 5.46, p = 0.026) relative to unstimulated cells plotted against LRRK2 median fluorescence intensity (MFI) of stimulated cells. ANCOVA was performed to assess differences of slopes between HC and PD. Linear regression was used to assess individual correlations of slopes of HC and PD. Significance was set at p < 0.05.

LRRK2 function may translate into poor regulation of T-cell responses and result in a pro-inflammatory environment characteristic of PD.

Cytokine secretion by T cells is a necessary step for promoting the immune response, but prolonged secretion and/or increased cytokine levels are hallmarks of inflammatory disease. In the CSF and nigrostriatal regions of PD brains examined at autopsy, the levels of pro-inflammatory cytokines such as IL-1β, TNF, IFN-γ, and IL-6 were increased compared to those of age-matched HC subjects. In the present studies, monocytes and T cells from PD patients were shown to secrete more pro-inflammatory cytokines than T cells from healthy individuals. In addition, both CD4+ and CD8+ T cells of PD patients expressing higher levels of inflammatory cytokines also expressed higher levels of LRRK2 suggesting that LRRK2 protein expression is associated with the inflammatory response characteristically seen in this neurodegenerative disease. Taken together, our findings suggest that LRRK2 levels in peripheral T cells may serve as a biomarker for diagnosis and monitoring disease progression in PD patients.

The significance of our findings are threefold. First, the selective induction of LRRK2 in pro-inflammatory monocytes and its potential regulatory role in antigen presentation is a crucial step in activation of the immune response and merits further exploration. Second, defining the kinetics of LRRK2 expression and its regulation in activated T cells is a critical first step toward understanding the role that LRRK2 plays in the adaptive immune system and its potential link to PD pathogenesis. Third, the positive correlations between LRRK2 expression levels in T-cell subsets, cytokine expression and secretion, and T-cell activation states suggest that targeting LRRK2 with therapeutic interventions is likely to have direct effects on immune cell function—whether this affords benefit or untoward bystander effects remains to be determined and is requisite to advancing LRRK2 kinase inhibitors to clinical trials.

MATERIALS AND METHODS

Human subjects

PD patients (40) and age-matched HCs (32) subjects were recruited through the Immune System and Neurological Disease (ISND) Institutional Review Board (IRB)-approved research protocol at the Emory Movement Disorders Clinic and community outreach events. Subjects were excluded based on age (younger than 50 and over 85 years of age), known familial PD mutations and/or other known neurological, chronic or recent infections, or autoimmune comorbidities. Subjects were genotyped for the G2019S LRRK2 mutation (LifeTechnologies #4351378, Grand Island, NY).

During recruitment, a confidential family history and environmental questionnaire was used to assess history of disease and inflammation/environmental exposures and comorbidities. Caffeine, nonsteroidal anti-inflammatory drug, and nicotine exposure was calculated as milligram-years, milligram-years, and pack-years, respectively. The study populations were balanced with respect to risk factors for PD, including age, smoking, nonsteroidal anti-inflammatory drug use, caffeine intake, and rs3129882 (HLA-DRA SNP) genotype (Supplementary Table 1). Study population was not sex-matched: the PD group was predominantly male while HC subjects tended to be more female as they were generally the caregivers; however, when the results are stratified by sex, sex does not account for the differences observed. Clinical severity of PD symptoms was...
also assessed using Hoenh and Yahr ratings and part II and III of the Unified Parkinson’s Disease Rating Scale.

Human PBMC isolation, stimulation, and purification
Isolation, stimulation, and purification of peripheral immune cells was performed as previously published in Kannarkat et al. Briefly, PBMCs were isolated from whole blood using density centrifugation with Ficoll-Paque (GE Healthcare, Uppsala, Sweden). Monocytes and T cells were isolated from PBMCs using positive selection columns with anti-CD14 and anti-CD3 paramagnetic beads, respectively (Miltenyi Biotec, Bergisch Gladbach, Germany). The isolated cell fraction was processed for flow cytometry as follows. Monocytes and T cells were plated for stimulation in a 12-well plate at a density of 1x10^6 cells per well. Monocytes were plated for 18 or 72 h with or without anti-CD3/CD28 beads (1:1 cells/beads) (Dynabeads® Life Technologies, Grand Island, NY, USA) and 30 U/mL recombinant human IL-2 (Biolegend, San Diego, CA, USA).

Mouse PBMC isolation
The following mouse strains were obtained from Jackson labs: B6.Cg-Tg (Lrrk2^{G2019S})*2Yu/J (*#012466), B6.Cg-Tg(Lrrk2^{G2019S})*2Yu/J (*#012466), C57BL/6J (*#000664), and C57BL/6-Lrrk2^{G2019S};J (*#012444). Blood from each mouse was collected from the tail, and individual slopes of HC and PD. All statistical tests used are indicated in the figure legends. Graphpad Prism Version 6.05 (Prism, La Jolla, CA, USA) software was used to perform all statistical analyses.

Human THP-1 monocytic cell culture and differentiation
THP-1 cells (ATCC #TIB-202) were maintained in RPMI1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1 mM sodium pyruvate and supplemented with 10% fetal bovine serum. THP-1 cells were terminally differentiated into macrophages by exposure to 100 nM of phorbol 12-myristate 12-acetate (PMA) (Sigma P-8139) for 72 h. Terminal differentiation was confirmed as cells become adherent. Stimulation with 200 U/mL IFN-γ for 18 h was performed to further increase LRRK2 protein levels. Trypsin was used to lift the differentiated cells prior to use in western blotting or flow cytometry. For flow cytometry, cells were permeabilized and stained intracellularly with Abcam c41-2 Rb anti-LRRK2 antibody (1:50) and either a secondary (1:10,000).

Western blotting
THP-1 cells and human monocytes were lysed in 4x sample buffer (Bio-Rad, Hercules, CA, USA) and heated at 80 °C for 5 min proteins were then separated in a 12% polyacrylamide gel (Bio-Rad) by gel electrophoresis and transferred to a 45 μm polyvinylidene difluoride (PVDF) membrane (Sigma Aldrich, St Louis, MO, USA). Following transfer, the membrane was cut along the pre-stained standard band indicating 100 kDa molecular weight and incubated in a 5% skim milk blocking solution in 1x Tris-buffered saline containing 0.1% Tween-20 (TBST) (Sigma Aldrich). The corresponding membrane sections were incubated overnight in blocking solution containing a primary antibody targeting either GAPDH (SC-31915, 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA) or LRRK2 (MUF c41-2, 1:5000; Abcam, Cambridge, UK) at 4 °C. Following three 5-min washes in 0.1% TBST with agitation, membrane sections were incubated for 1 h at room temperature in either goat anti-rabbit (LRRK2) or rabbit anti-goat (GAPDH) horseradish peroxidase conjugated secondary antibodies (1:1000; Jackson ImmunoResearch, West Grove, PA, USA) in blocking solution. Membranes were again washed in 0.1% TBST, and imaged using 1:1 dilute SuperSignal West FemtoChemiluminescent Substrate (Thermo Scientific, Waltham, MA, USA). Band intensity was determined using Image Studio Software (Li-Cor, Lincoln, NE, USA). LRRK2 expression (∼286 kDa) has been normalized to corresponding GAPDH (Fig. 1b; 37 kDa).

Flow cytometry analysis
To stain for flow cytometry, 5 x 10^6 cells per well were washed once with PBS and incubated for 30 min at 4 °C with LIVE/DEAD Fixable Red (Life Technologies). Cells were incubated in 1x FACS buffer (1% bovine serum albumin, 0.1% sodium azide, and 1 mL EDTA) for 15 min at 37 °C with anti-human CCR7:phycoerythrin. Cells were washed and incubated for 20 min at 4 °C with surface antibodies detailed in Supplementary Table 2. Cells were intracellularly stained using the Fixation/Permeabilization Stain Kit per manufacturer’s protocol (eBiosciences, San Diego, CA, USA). ICS was performed on T cells stimulated for 18 h. Cells were incubated with 5 μg/mL Brefeldin A (Biolegend) for 7 h prior to harvest. After harvest, cells were processed according to protocols detailed above. Cells were run immediately on an LSRII instrument (BD Biosciences, Franklin Lakes, NJ, USA). Supernova Spherobeads (Spherotech, Lake Forest, CA, USA), and OneComp Beads (eBiosciences) were used to set voltages and compensation settings between cytometry runs. Analysis of flow cytometry data was performed using FlowJo Software v10.X (Ashland, OR, USA). Gates were set according to Supplementary Fig. S5. Because the LRRK2 antibody is un conjugated, a secondary antibody only control condition was used to determine nonspecific binding and select for positively stained populations. Conjugated isotype control antibodies were used for the rest of the cellular protein markers stained. Fluorescence minus one controls were used to account for fluorescence spillover between channels. Protein expression levels are reported as MFI.

Cell proliferation assays
To assess T-cell proliferation, cells were stained with CellTrace Violet (Life Technologies) according to the manufacturer’s protocol and plated for 72 h with or without anti-CD3/CD28 Dynabeads® and 30 U/mL recombinant human IL-2. Unstimulated cells were harvested at 18 h post-plating as cells do not remain viable for 72 h without stimulation. At harvest, Dynabeads® were removed using magnetic separation, washed, and stained according to the above flow analysis protocol.

Meso scale discovery multiplexed immunoassays
Conditioned media from plated cells was collected during cell harvest and stored at -80 °C until sample analysis. Media analyze levels were measured in duplicate using 3-plex (IL-2, TNF-α, and IFN-γ) and 10-plex (IFN-γ, IL-10, IL-12p70, IL-13, IL-1β, IL-4, IL-6, IL-8, and TNFα) plates on a Sector 2400 instrument (Meso Scale Discovery, Rockville, MD, USA).

Statistical analyses
A two-tailed Student’s t-test was used to make comparisons between HC subjects and PD patients in the immunophenotyping studies. A two-way analysis of variance (ANOVA) followed by Sidak’s multiple comparisons post-hoc test was used to compare baseline characteristics of the study population and inducibility of immune response following IFN-γ stimulation in monocytes or anti-CD3/CD28 stimulation in T cells. Data was plotted with means and standard error of the mean. Analysis of covariance (ANCOVA) was used to assess differences in slopes of correlations between HC and PD. Linear regressions were performed to assess correlations of individual slopes of HC and PD. All statistical tests used are indicated in the figure legends. GraphPad Prism Version 6.05 (Prism, La Jolla, CA, USA) software was used to perform all statistical analyses.
Human subjects research approval
All procedures involving human subjects were approved by the IRB of Emory University in Atlanta, Georgia before study commenced. All participants provided written informed consent and the terms and risks of the study were thoroughly explained before inclusion in the study.

ACKNOWLEDGEMENTS
We thank members of the Boss and Tansey laboratories for helpful discussions. We also thank E. Sperin and K. Tansey for assistance with blood collection, and V. Herzberg for assistance with biostatistical analyses. Thanks to the Michael J. Fox Foundation for Parkinson’s Research, American Parkinson’s Disease Association, Wilkin’s Parkinson’s Foundation, and Emory Udall Center of Excellence for Parkinson’s Research for facilitating study recruitment. Financial support for the authors was provided by the Michael J. Fox Foundation for Parkinson’s Research LR2K in Idiopathic PD program (MGT, JMB), IR21NS084647 from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (M.G.T, J.M.B.), the Sartan Lanier Family Foundation (S.A.F.), pre-doctoral training grant ST32 A0076510 from the National Institutes of Health/National Institute of Allergy and Infectious Disease (D.A.C.), NRSA award 1F31NS081830-01 from the National Institute of Neurologic Disorders and Stroke (G.T.K.), and post-doctoral training grant ST32 ES 12870-12 from the National Institute of Environmental Health Sciences (A.F.C.), and NRSA award 1F31NS098673-01 from the National Institute of Neurologic Disorders and Stroke (L.M.B.). This study was also supported in part by the Emory Multiplexed Immunoassay Core (EMIC), which is subsidized by the Emory University School of Medicine and is one of the Emory Integrated Core Facilities. Additional support was provided by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number ULTR000454. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.

COMPETING INTERESTS
The authors declare no competing interests.

REFERENCES
1. Pasan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44, 595–600 (2004).
2. Zimprich, A. et al. Mutations in LR2K cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004).
3. Thaler, A., Ash, E., Gan-Or, Z., Orr-Utregge, A. & Giladi, N. The LR2K G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews. J. Neurol. Transm. 116, 1473–1482 (2009).
4. Aasly, J. O. et al. Clinical features of LR2K-associated Parkinson’s disease in central Norway. Ann. Neurol. 57, 762–765 (2005).
5. Haugavoll, K. et al. Lrrk2 R1414C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70, 1456–1460 (2008).
6. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P. & Gallo, K. A. LR2K in Parkinson’s disease: protein domains and functional insights. Trends Neurosci. 29, 286–293 (2009).
7. Funayama, M. et al. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301 (2002).
8. Guo, L. et al. The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LR2K), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658–3670 (2007).
9. Gilbsbach, B. K. et al. Roco kinase structure gives insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc. Natl Acad. Sci. USA 109, 10322–10327 (2007).
10. Manzon, C. et al. mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. Sci. Rep. 6, 35106 (2016).
11. Ferrazza, R. et al. LR2K deficiency impacts ceramide metabolism in brain. Biochem. Biophys. Res. Commun. 478, 1141–1146 (2016).
12. Plowey, E. D., Cherra, S. J., Liu, Y. J. & Chu, C. T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 105, 1048–1056 (2008).
13. Schapsinsky, J., Nardozzi, J. D., Felizia, F. & LaVoie, M. J. Membrane recruitment of endogenous LR2K precedes its potent regulation of autophagy. Hum. Genet. 23, 4201–4214 (2014).
14. Ramamonjisoa, D. et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LR2K. PLoS ONE 6, e15856 (2011).
15. Berwick, D. C. & Harvey, K. LR2K functions as a Wnt signaling scaffold, bridging cystotic proteins and membrane-localized LR6. Hum. Genet. 21, 4966–4979 (2012).
45. Kannarkat, G. T. et al. Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case-control study. *NPJ Parkinsons Dis.* **1**, 15002 (2015).

46. Gibson, H. M. et al. Induction of the CTLA-4 Gene in human lymphocytes is dependent on NFAT binding the proximal promoter. *J. Immunol.* **179**, 3831–3840 (2007).

47. Mount, M. P. et al. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. *J. Neurosci.* **27**, 3328–3337 (2007).

48. Mogi, M. et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. *Neurosci. Lett.* **180**, 147–150 (1994).

49. Blum-Degen, D. et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. *Neurosci. Lett.* **202**, 17–20 (1995).

50. Chen, H. et al. Smoking duration, intensity, and risk of Parkinson disease. *Neurology* **74**, 878–884 (2010).

51. Gagne, J. J. & Power, M. C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. *Neurology* **74**, 995–1002 (2010).

52. Hernán, M. A., Takkouche, B., Caamaño-Isorna, F. & Gestal-Otero, J. J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. *Ann. Neurol.* **52**, 276–284 (2002).

53. Chen, H. et al. Nonsteroidal anti-inflammatory drugs and the risk of parkinson disease. *Arch. Neurol.* **60**, 1059–1064 (2003).

Supplementary Information accompanies the paper on the *npj Parkinson’s Disease* website (doi:10.1038/s41531-017-0010-8).